GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » SomaLogic Inc (NAS:SLGC) » Definitions » ROE % Adjusted to Book Value

SomaLogic (SomaLogic) ROE % Adjusted to Book Value : -19.25% (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is SomaLogic ROE % Adjusted to Book Value?

SomaLogic's ROE % for the quarter that ended in Sep. 2023 was -17.52%. SomaLogic's PB Ratio for the quarter that ended in Sep. 2023 was 0.91. SomaLogic's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2023 was -19.25%.

SomaLogic ROE % Adjusted to Book Value Historical Data

The historical data trend for SomaLogic's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SomaLogic ROE % Adjusted to Book Value Chart

SomaLogic Annual Data
Trend Dec20 Dec21 Dec22
ROE % Adjusted to Book Value
- -6.36 -22.13

SomaLogic Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.20 -40.25 -27.69 -22.46 -19.25

Competitive Comparison of SomaLogic's ROE % Adjusted to Book Value

For the Health Information Services subindustry, SomaLogic's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SomaLogic's ROE % Adjusted to Book Value Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, SomaLogic's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where SomaLogic's ROE % Adjusted to Book Value falls into.


SomaLogic ROE % Adjusted to Book Value Calculation

SomaLogic's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2022 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-18.59% / 0.84
=-22.13%

SomaLogic's ROE % Adjusted to Book Value for the quarter that ended in Sep. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-17.52% / 0.91
=-19.25%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SomaLogic ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of SomaLogic's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

SomaLogic (SomaLogic) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » SomaLogic Inc (NAS:SLGC) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
HCAT SHCR AMWL ACCD SPOK TALK TRHC SOPH LFMD CPSI GEHC VEEV TSE:2413 HQY ASX:PME RCM TXG DOCS PGNY TDOC
Traded in Other Exchanges
N/A
Address
2945 Wilderness Place, Boulder, CO, USA, 80301
Website
https://www.somalogic.com
SomaLogic is a commercial-stage proteomics company. It operates as a protein biomarker discovery and clinical diagnostics company that develops slow off-rate modified aptamers, which are modified nucleic acid-based protein binding reagents that are specific for their cognate protein. The Somamers/SomaScan technology enables researchers to analyze various types of biological samples for protein biomarker signatures, which can be utilized in drug discovery and development.
Executives
Alison Marie Roelke officer: Chief People Officer 900 INNOVATORS WAY, SIMI VALLEY CA 93065
Adam Taich officer: Interim CEO C/O SOMALOGIC, INC., 2945 WILDERNESS PLACE, BOULDER CO 80301
Ruben Gutierrez officer: General Counsel 6435 AVENIDA WILFREDO, LA JOLLA CA 92037
Kathy L Hibbs director C/O VIROLOGIC, 345 OYSTER POINT BLVD, SOUTH SAN FRANCISCO CA 94080
Jason Ryan director C/O FOUNDATION MEDICINE, INC., ONE KENDALL SQUARE, SUITE B3501, CAMBRIDGE MA 02139
Thomas D. Carey director 8 PAIGE STREET, HINGHAM MA 02043
Eliot M Lurier officer: Interim CFO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Tycho Peterson director C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109
Eli Casdin director 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Shaun M. Blakeman officer: Chief Financial Officer C/O CANTEL MEDICAL CORP., 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Anne H. Margulies director C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Richard A Post director 998 LACOSTA LANE, LANE TREE CO 80124
Charles M. Lillis director 13 CASTLE PINES DRIVE N, CASTLE ROCK CO 80108
Stephen Quake director C/O FLUIDIGM CORPORATION, 7000 SHORELINE COURT, SUITE 100, SOUTH SAN FRANCISCO CA 94080
Robert Barchi director